Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.40 |
| ▸ | ACHE | P22303 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5121535 | 0.81 | DRD2 (0.47) | FAAHHCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL5131977 | 0.80 | REV1 (0.57) | FAAHKMT2A | |
| SCHEMBL3050133 | 0.78 | DHCR7 (0.55) | CA2CA9ACHEMEN1KMT2A | |
| SCHEMBL3061751 | 0.78 | CHRNA7 (0.51) | CA2CA9 | |
| SCHEMBL18098775 | 0.76 | CA2 (0.70) | CA2CA9ACHEMEN1KMT2A | |
| SCHEMBL5127723 | 0.75 | REV1 (0.54) | FAAHKMT2A | |
| SCHEMBL5125860 | 0.75 | REV1 (0.54) | FAAHKMT2A | |
| SCHEMBL5128457 | 0.73 | FAAH (0.43) | FAAHHCRTR1HCRTR2ACHEMEN1 | |
| SCHEMBL3061503 | 0.72 | CHRNA7 (0.52) | CA2CA9 | |
| SCHEMBL5131159 | 0.71 | REV1 (0.56) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161344-A1 | Melanin Concentrating Hormone Receptor Ligands: Substituted Tetrahydroisoquinoline Analogues | NEUROGEN CORPORATION | 2008-07-03 | — | — | US | claimed |
| WO-2005077903-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED TETRAHYDROISOQUINOLINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-08-25 | — | — | WO | claimed |
| US-20080161344-A1 | Melanin Concentrating Hormone Receptor Ligands: Substituted Tetrahydroisoquinoline Analogues | NEUROGEN CORPORATION | 2008-07-03 | — | — | US | disclosed |
| US-20080161344-A1 | Melanin Concentrating Hormone Receptor Ligands: Substituted Tetrahydroisoquinoline Analogues | NEUROGEN CORPORATION | 2008-07-03 | — | — | US | disclosed |
| US-20080161344-A1 | Melanin Concentrating Hormone Receptor Ligands: Substituted Tetrahydroisoquinoline Analogues | NEUROGEN CORPORATION | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161344-A1 | Melanin Concentrating Hormone Receptor Ligands: Substituted Tetrahydroisoquinoline Analogues | MCHR1, MCHR2, MC1R | CA2 4693/4885CA9 4702/4885FAAH 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.